Kyle Fink, PhD

Kyle Fink, PhD


Following a PhD from Central Michigan, a PhD from the University of Nantes, and an NIH-sponsored postdoc at the UC Davis Institute for Regenerative Cures, Dr. Fink was awarded space and resources from the Neurology Department and the Institute for Regenerative Cures to form an independent team, as a PI in 2017. The Fink laboratory focuses on the therapeutic development of gene modifying modalities such as CRISPR/Cas9 to treat genetically-linked neurological disorders. His key interest in this field involves understanding the therapeutic benefit in human cellular models of disease, functional efficacy in transgenic rodent models, and optimization of delivery modalities in clinically-relevant models.